January 28, 2013

Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?

.   .   

The side-effect profile of cyclophosphamide is well-known and most clinicians only prescribe it in the most severe disease. This review compares cyclophosphamide to mycophenolate mofetil for induction and maintenance therapy for severe lupus nephritis. Using the available evidence, the authors conclude that mycophenolate mofetil is a viable alternative for therapy, although cyclophosphamide may have a role under specific circumstances.

Related Articles:

Glomerulonephritis, Review

Comments are closed.